Significant differences in median survival between I-A, I-CF, and I-X signatures were not observed among the grade II glioma patients or grade II-III oligodendrogliomas, or between CIC and FUBP1 mutated patients (Supplementary Fig. 2). Here, FUBP1 is linked to central nervous system cancer.